These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Editorial: HIV and Antiretroviral Drugs: Current Status and New Challenges. Nikolopoulos G; Bonovas S Curr Pharm Des; 2017; 23(18):2551. PubMed ID: 28425865 [No Abstract] [Full Text] [Related]
48. Will CURE trials introduce an uncomfortable revolution in the field of HIV research? Protière C; Préau M; Doumergue M; Mora M; Lambotte O; Spire B; Suzan-Monti M HIV Clin Trials; 2017 Jul; 18(4):174-175. PubMed ID: 28587569 [No Abstract] [Full Text] [Related]
49. HIV viral load markers in clinical practice. Saag MS; Holodniy M; Kuritzkes DR; O'Brien WA; Coombs R; Poscher ME; Jacobsen DM; Shaw GM; Richman DD; Volberding PA Nat Med; 1996 Jun; 2(6):625-9. PubMed ID: 8640545 [TBL] [Abstract][Full Text] [Related]
51. The antiproliferative agents trans-bis(resorcylaldoximato)copper(II) and trans-bis(2,3,4-trihydroxybenzaldoximato)copper(II) and cytopathic effects of HIV. Elo H Z Naturforsch C J Biosci; 2004; 59(7-8):609-11. PubMed ID: 15813388 [TBL] [Abstract][Full Text] [Related]
52. Editorial: Extra-Cellular Factors as New Anti-HIV Therapeutic Target. Federico M Curr Drug Targets; 2016; 17(1):3. PubMed ID: 26687603 [No Abstract] [Full Text] [Related]
53. [III. IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 24-27 July 2005. Part 2]. Marcus U Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):310-7. PubMed ID: 16465519 [No Abstract] [Full Text] [Related]
54. HIV-1 and HAART: a time to cure, a time to kill. Saag MS; Kilby JM Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490 [No Abstract] [Full Text] [Related]
55. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects]. Marcello A; Giacca M Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891 [No Abstract] [Full Text] [Related]
56. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087 [TBL] [Abstract][Full Text] [Related]
57. [Surrogate endpoints in clinical studies exemplified by HIV infection]. Furrer H Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1079-88. PubMed ID: 9691341 [TBL] [Abstract][Full Text] [Related]
58. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward. Abbas UL; Mellors JW Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421 [No Abstract] [Full Text] [Related]
59. Effect of antiretroviral therapy on plasma HIV RNA. Saag MS J Biol Regul Homeost Agents; 1995; 9(3):105-6. PubMed ID: 8782017 [No Abstract] [Full Text] [Related]